REGENXBIO (NASDAQ:RGNX) Price Target Cut to $34.00 by Analysts at HC Wainwright

REGENXBIO (NASDAQ:RGNX) had its price objective decreased by HC Wainwright from $36.00 to $34.00 in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. Raymond James assumed coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target on the stock. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Friday. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Finally, The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

REGENXBIO Trading Up 4.2 %

NASDAQ:RGNX opened at $7.00 on Monday. REGENXBIO has a 1 year low of $5.62 and a 1 year high of $23.14. The firm’s fifty day simple moving average is $7.29 and its 200 day simple moving average is $8.97. The firm has a market capitalization of $346.82 million, a PE ratio of -1.39 and a beta of 1.35.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million for the quarter, compared to analyst estimates of $23.70 million. As a group, analysts anticipate that REGENXBIO will post -4.84 EPS for the current fiscal year.

Hedge Funds Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its holdings in REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the last quarter. FMR LLC lifted its holdings in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in REGENXBIO during the 4th quarter valued at about $54,000. Dynamic Technology Lab Private Ltd bought a new position in REGENXBIO during the 4th quarter valued at about $79,000. Finally, Laurion Capital Management LP bought a new position in REGENXBIO during the 4th quarter valued at about $79,000. 88.08% of the stock is owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.